Company news
News Center
News center
202412-26
Our new website has launched on December 26, 2024.
Our website have a revision and upgrade. The new one is launched on December 26,2024.
202409-14
Congratulations to Lunarsun on the Successful Approval of Tigecycline for Injection!
Beijing Lunarsun Pharma is excited to announce that Tigecycline for Injection was approved for production on September 14, 2024.
Approval Number: H20244853
We look forward to discussing potential partnerships with interested pharmaceutical manufacturers.
202408-05
Congratulations to Lunarsun on the Successful Approval of Famotidine Injection!
Beijing Lunarsun Pharma is pleased to share that the Famotidine Injection was approved for production on on August 5, 2024
Approval Number: H20244490
We welcome inquiries from pharmaceutical companies interested in collaboration.
202401-18
Congratulations to Lunarsun on the Successful Status Upgrade of Mirabegron to “Active”!
Beijing Lunarsun Pharma is proud to announce that the imported API Mirabegron was successfully approved for turning into “Active ”on January 18, 2024.
Registration Number: Y20210000398
We warmly invite pharmaceutical manufacturers to reach out for collaboration opportunities.
202302-24
Welcome to Qingdao API Exhibition!
Qingdao API Exhibition
Time: December 14, 2023
Location: Qingdao
Booth number: N4 H12
Welcome new and old customers to visit and negotiate!
202203-29
Congratulations to Lairuisen Pharmaceuticals on the public announcement of their new active pharmaceutical ingredients, oseltamivir and everalen!
In March 2022, congratulations to Lairuisen Pharmaceuticals on successfully passing the evaluation and activating the registration status "A" for the import declaration of raw materials oseltamivir and efaviren. Welcome to cooperate.
